A federal appeals court has significantly curtailed access to mifepristone, a commonly used abortion medication, by prohibiting its distribution through the mail. The ruling from a panel of the New Orleans-based 5th U.S. Circuit Court of Appeals mandates that the abortion pill must now be dispensed exclusively in person at clinics.
Court Ruling and Rationale
The panel asserted in its decision: "Every abortion facilitated by FDA’s action cancels Louisiana’s ban on medical abortions and undermines its policy that ‘every unborn child is human being from the moment of conception and is, therefore, a legal person.’" This marks a departure from the historical judicial deference typically granted to the Food and Drug Administration (FDA) regarding drug safety and regulation.
Background on Mifepristone
Mifepristone was approved by the FDA in 2000 as a safe and effective method for terminating early pregnancies. It is usually used in combination with misoprostol, a second drug. Due to rare instances of excessive bleeding, the FDA initially imposed strict limitations on who could prescribe and distribute the pill—only specially certified physicians, and only after an in-person appointment where the patient received the medication.
During the COVID-19 pandemic, those requirements were lifted. At that time, FDA officials under President Joe Biden stated that after more than two decades of monitoring mifepristone use and reviewing numerous studies involving thousands of women, it was evident that the pill could be used safely without direct supervision.
Impact on Access
Since the Supreme Court’s 2022 decision overturning Roe v. Wade and allowing states to enforce abortion bans, prescriptions by mail have become a major avenue for obtaining abortions, including in states with bans. The new ruling is expected to severely affect access to abortion and miscarriage care across the country.
Julia Kaye, a lawyer with the American Civil Liberties Union, stated: "This is going to affect patients’ access to abortion and miscarriage care in every state in the nation. When telemedicine is restricted, rural communities, people with low incomes, people with disabilities, survivors of intimate partner violence and communities of color suffer the most."
Legal and Political Context
FDA officials under President Donald Trump have stated that the agency is conducting a new safety review of mifepristone at the president’s direction. The judges noted that the FDA "could not say when that review might be complete and admitted it was still collecting data."
In a court filing, Louisiana’s attorney general and a woman who claimed she was coerced into taking abortion pills requested that the FDA rules be rolled back to require in-person prescribing and dispensing. A Louisiana-based federal judge had previously ruled that the allowances undermined the state’s abortion ban but stopped short of immediately reversing the regulations.
Next Steps
Friday’s ruling sets the stage for a likely appeal to the Supreme Court. The conservative-majority high court overturned the nationwide right to abortion in 2022 but unanimously preserved access to mifepristone two years later. That 2024 decision sidestepped the core issues, however, by ruling that the anti-abortion doctors behind the case lacked legal standing to sue.
